<DOC>
	<DOCNO>NCT01501396</DOCNO>
	<brief_summary>This randomized phase II trial study safety efficacy megestrol acetate give without mirtazapine treat cancer patient weight loss loss appetite . To date , pharmacologic intervention approve FDA treat cancer anorexia-cachexia syndrome ( CACS ) . Megestrol acetate show increase appetite cancer patient . Adding mirtazapine may provide much effective treatment help improve quality life .</brief_summary>
	<brief_title>Megestrol Acetate With Without Mirtazapine Treating Cancer Patients With Weight Loss Loss Appetite</brief_title>
	<detailed_description />
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Patient must histologically cytologically confirm solid malignancy Patient must &gt; =18 year old . Patient must show unintentional weight loss &gt; = 5 % 6 week date back time consent &gt; = 10 % 6 month date back time consent Patient must poor appetite ( define score = &lt; 14 Simplified Nutritional Appetite Questionnaire ( SNAQ ) Prior diagnostic therapeutic surgery allow long wound fully heal , patient fully recovered procedure , least 4 week elapsed procedure ; needle core biopsy , minimally invasive procedure chest tube placement , 4week recovery period apply , patient must recover fully procedure Concomitant administration chemotherapy permit require Prior radiation therapy allow local symptom palliation prior start treatment long least 2 week elapsed procedure patient fully recover treatmentrelated toxicity Patient must Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Patient must normal organ marrow function define : Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamic pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x institutional upper limit normal Creatinine within normal institutional limit OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Patient must able understand willing sign write informed consent document Patient must receive investigational agent Patient must receive tube feed parenteral nutrition Patient must take either MA MRZ within 4 week prior enrol study , prior use either MA MRZ 4 week enrollment allow Patient must take medication appetite stimulation within 4 week prior enrol study ; prior use appetite stimulant 4 week enrollment allow Patient must know seizure disorder Patient must receive abdominal radiation within 4 week enrol study ; patient receive abdominal radiation 4 week prior enrollment may participate study , long recovered toxicity radiation therapy Patient must take chronic systemic corticosteroid ( e.g. , prednisone , dexamethasone ) within 4 week prior study entry study ( unless premedication chemotherapy ) Patient must moderate severe depression define score &gt; = 20 Center Epidemiologic Studies Depression Scale ( CESD ) Patient must take antidepressant therapy within 4 week prior study entry Patient must antipsychotic therapy risperidone , quetiapine , clozapine , phenothiazine , butyrophenone 30 day prior study ; patient may receive prochlorperazine phenothiazine antiemetic therapy Patient must history phenylketonuria ( MRZ compound contain phenylalanine ) Patient must active dysphagia gastrointestinal tract obstruction Patient must previous history deep venous thrombosis , pulmonary embolism , thrombophlebitis Patient must receive agent increase appetite weight growth hormone ( GH ) , insulinlike growth factor ( IGF1 ) , growth hormonereleasing hormone , insulinlike growth factor bind protein3 ( IGFBP3 ) , cannabinoids within 6 week prior study entry Patient must body mass index ( BMI ) &gt; 30 Patient must history allergic reaction attribute compound similar chemical biologic composition MA MRZ Patient must uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Mirtazapine cause nonteratogenic adverse effect develop human fetus recommend therapeutic dose ; reason MA well therapeutic agent use trial know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately ; woman childbearing potential must negative pregnancy test prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>